Technical Analysis for SVRA - Savara, Inc.

Grade Last Price % Change Price Change
D 4.77 1.17% 0.06
SVRA closed unchanged on Monday, March 18, 2024, on 72 percent of normal volume. The price action carved out a bullish hammer (or hammer-like) candlestick pattern. That may indicate an upside reversal. Look for price to trade above the high of the hammer for confirmation. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
Earnings due: Mar 28
*** please verify all earnings dates ***
2 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Down Down

Date Alert Name Type % Chg
MACD Bearish Centerline Cross Bearish 1.17%
Hammer Candlestick Bullish 1.17%
Stochastic Buy Signal Bullish 1.17%
Lizard Bullish Bullish Day Trade Setup 1.17%
Doji - Bullish? Reversal 1.17%
Lower Bollinger Band Touch Weakness 1.17%
Oversold Stochastic Weakness 1.17%
Oversold Stochastic Weakness 1.17%
Fell Below 50 DMA Bearish 2.25%
Oversold Stochastic Weakness 2.25%

   Recent Intraday Alerts

Alert Time
Reversed from Down 9 minutes ago
Lizard Bullish Entry 9 minutes ago
Hammer Candlestick Entry 9 minutes ago
Rose Above Previous Day's High 9 minutes ago
Up 1% 9 minutes ago

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Savara, Inc. Description

Savara Inc., formerly Mast Therapeutics, Inc., is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients. Molgradex is an inhaled formulation of recombinant human granulocyte-macrophage colony-stimulating factor. It is developing Molgradex for the treatment of autoimmune pulmonary alveolar proteinosis, a rare lung disease. AIR001 is a sodium nitrite solution for inhalation via nebulization. AIR001 is in Phase II clinical development for the treatment of heart failure with preserved ejection fraction, also known as diastolic heart failure or heart failure with preserved systolic function.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Pharmaceutical Clinical Development Heart Failure Respiratory Diseases Stage Pharmaceutical Cystic Fibrosis Heart Disease Staphylococcus Aureus Treatment Of Heart Failure Lung Infection Methicillin Vancomycin

Is SVRA a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 5.7
52 Week Low 1.63
Average Volume 856,730
200-Day Moving Average 3.92
50-Day Moving Average 4.85
20-Day Moving Average 5.08
10-Day Moving Average 5.05
Average True Range 0.24
RSI (14) 41.86
ADX 20.71
+DI 21.46
-DI 29.33
Chandelier Exit (Long, 3 ATRs) 4.98
Chandelier Exit (Short, 3 ATRs) 5.24
Upper Bollinger Bands 5.63
Lower Bollinger Band 4.52
Percent B (%b) 0.17
BandWidth 21.75
MACD Line -0.02
MACD Signal Line 0.07
MACD Histogram -0.0877
Fundamentals Value
Market Cap 637.46 Million
Num Shares 135 Million
EPS -0.31
Price-to-Earnings (P/E) Ratio -15.19
Price-to-Sales 131146.00
Price-to-Book 4.51
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 5.04
Resistance 3 (R3) 5.01 4.88 4.99
Resistance 2 (R2) 4.88 4.79 4.89 4.97
Resistance 1 (R1) 4.79 4.74 4.82 4.82 4.95
Pivot Point 4.66 4.66 4.67 4.67 4.66
Support 1 (S1) 4.57 4.57 4.60 4.60 4.47
Support 2 (S2) 4.44 4.52 4.45 4.45
Support 3 (S3) 4.35 4.44 4.44
Support 4 (S4) 4.38